Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AloFem: Allogeneic mesenchymal stem cells for osteonecrosis of the femoral head after allogeneic stem cell transplantation
2018-000886-35Phase 2Active
- Sponsor
- Enrique Gomez-Barrena
- Start
- Apr 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stromal cells in osteonecrosis of the hip, sponsored by Enrique Gomez-Barrena. Primary endpoint: Early local complication rate. Started Apr 2018; status: active.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
osteonecrosis of the hip
Beyond the preview
Go deeper on 2018-000886-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000886-35.